Photo: Granma

Almost 10 years after the treatment was first introduced into the country’s healthcare system (with a pilot test undertaken in the province of Sancti Spíritus, in June 2007), today over 65,000 Cubans nationwide have benefited from Heberprot-P.
The medication, developed by a team of researchers at the country’s Center for Genetic Engineering and Biotechnology (CIGB), is designed to treat advanced stage diabetic foot ulcers, has been proven to significantly reduce the risk of amputation in almost 80% of all cases, and is the only treatment of its kind in the world.
Registered in over 20 nations, Heberprot-P has received the Gold Medal from the World Intellectual Property Organization, and been used to treat around 250,000 people worldwide. Before the medication was created, there existed no effective treatment for people suffering from advanced stage diabetic foot ulcers.
Speaking to Granma, Iris Lugo, CIGB communications specialist, reported that Havana’s Riviera Hotel will host the 19th National Encounter on the Expansion of the Comprehensive Program to Treat Patients with Diabetic Foot Ulcers using Heberprot-P, May 11-12.
Organized by the Ministry of Public Health in collaboration with the CIGB, the event will see the participation of over 250 specialists in Angelology and Vascular Surgery who, among other topics, will review the performance and key results of the program.